View in EDS HTML Full Text PDF Full Text

Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.

Saved in:
Bibliographic Details
Title: Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.
Authors: Schindler SE; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA., Petersen KK; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA., Saef B; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA., Tosun D; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA., Shaw LM; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Zetterberg H; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; UK Dementia Research Institute Fluid Biomarkers Laboratory, UK DRI at UCL, London, UK.; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, UK.; Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA., Dage JL; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.; Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA., Ferber K; Biogen, Biomarkers Group, Cambridge, Massachusetts, USA., Triana-Baltzer G; Neuroscience Biomarkers, Johnson and Johnson Innovative Medicine, San Diego, California, USA., Du-Cuny L; AbbVie, Ludwigshafen am Rhein, Rheinland-Pfalz, Germany., Li Y; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA., Coomaraswamy J; Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA., Baratta M; Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA., Mordashova Y; AbbVie, Ludwigshafen am Rhein, Rheinland-Pfalz, Germany., Saad ZS; Neuroscience Biomarkers, Johnson and Johnson Innovative Medicine, San Diego, California, USA., Raunig DL; Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA., Ashton NJ; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.; Banner Alzheimer's Institute, Phoenix, Arizona, USA.; Banner Sun Health Research Institute, Sun City, Arizona, USA., Meyers EA; Alzheimer's Association, Chicago, Illinois, USA., Rubel CE; Biogen, Biomarkers Group, Cambridge, Massachusetts, USA., Rosenbaugh EG; The Foundation for the National Institutes of Health, North Bethesda, Maryland, USA., Bannon AW; AbbVie, North Chicago, Illinois, USA., Potter WZ; Highly qualified expert, Philadelphia, Pennsylvania, USA.
Corporate Authors: Alzheimer's Disease Neuroimaging Initiative (ADNI) Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer's Disease Project Team
Source: Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Nov; Vol. 20 (11), pp. 8074-8096. Date of Electronic Publication: 2024 Oct 12.
Publication Type: Journal Article; Comparative Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: John Wiley & Sons, Ltd Country of Publication: United States NLM ID: 101231978 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-5279 (Electronic) Linking ISSN: 15525260 NLM ISO Abbreviation: Alzheimers Dement Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1552-5279
DOI:10.1002/alz.14315